Eli Lilly Inks $1.26B Licensing Deal with Hanmi for Sonefpeglutide

Eli Lilly (ticker: LLY) has signed an exclusive licensing agreement with South Korea's Hanmi to develop and commercialize sonefpeglutide, an experimental dual GLP-1/GCG receptor agonist for obesity. Under the terms, Hanmi will receive $75 million upfront and is eligible for up to $1.185 billion in development and regulatory milestone payments, for a total potential value of $1.26 billion.

Deal Details

• Total Value: $1.26 billion
• Upfront Payment: $75 million
• Milestone Payments: Up to $1.185 billion
• Product: Sonefpeglutide (dual GLP-1/GCG agonist)
• Rights: Exclusive worldwide except China and Korea

Rationale

Eli Lilly aims to strengthen its obesity portfolio amid growing demand for weight-loss therapies. Sonefpeglutide has shown promise in early trials for weight reduction and glycemic control. For Hanmi, the deal provides significant capital to advance its pipeline.

Regulatory Challenges

The deal may face review by the Committee on Foreign Investment in the United States (CFIUS) given the cross-border nature. Additionally, sonefpeglutide must successfully complete Phase 3 trials before seeking FDA approval.

Stock Impact

Eli Lilly's stock (LLY) showed minimal reaction to the announcement, as the deal is relatively small compared to the company's over $800 billion market cap. However, successful commercialization could boost Lilly's revenue in the obesity market.